PHARMACOTHERAPY OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN ADULTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2015-2025)
DOI:
https://doi.org/10.56238/levv17n60-025Keywords:
ADHD, Adults, Methylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Meta-Analysis, Randomized Controlled TrialAbstract
Background: Attention-deficit/hyperactivity disorder (ADHD) affects approximately 2.5% of the adult population globally. Multiple pharmacological agents are available, yet comparative efficacy and safety data remain limited.Objective: To systematically review and meta-analyze the efficacy, safety, and tolerability of pharmacological treatments for adults with ADHD using randomized controlled trials (RCTs) published between 2015 and 2025. Methods: Systematic searches were conducted in PubMed/MEDLINE, Embase, and Cochrane Library for double-blind, placebo-controlled RCTs in adults (≥18 years) with ADHD diagnosed according to DSM-IV, DSM-5, or ICD-10/11 criteria. Primary outcome was symptom reduction measured by validated scales (ADHD-RS, Conners, SNAP-IV). Secondary outcomes included adverse events, discontinuation rates, and functional improvement. Risk of bias was assessed using Cochrane RoB 2.0. Meta-analysis employed random-effects models with standardized mean differences (SMD) and 95% confidence intervals (CI). Heterogeneity was evaluated using I² statistics. GRADE methodology was applied to assess evidence quality. Results: Thirty-seven RCTs (n=2,289 adults) were included. Methylphenidate extended-release demonstrated the largest effect size (SMD: −0.92; 95% CI: −1.08 to −0.76), followed by lisdexamfetamine (SMD: −0.96; 95% CI: −1.17 to −0.76), mixed amphetamine salts (SMD: −0.81; 95% CI: −0.95 to −0.67), and atomoxetine (SMD: −0.48; 95% CI: −0.64 to −0.33). Guanfacine showed moderate efficacy (SMD: −0.66; 95% CI: −0.94 to −0.38). Stimulants demonstrated superior acceptability compared to non-stimulants. Adverse events were generally mild and dose-dependent. Heterogeneity was moderate (I²: 30–50%). Conclusion: Stimulant medications, particularly methylphenidate and lisdexamfetamine, represent first-line pharmacological treatments for adults with ADHD, with large effect sizes and favorable tolerability profiles. Non-stimulants offer alternatives for patients with contraindications or comorbidities. Evidence quality ranges from moderate to high for stimulants and low to moderate for non-stimulants.
Downloads
References
1. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-1250. doi:10.1016/S0140-6736(15)00238-X
2. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
4. Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007;20(4):386-392. doi:10.1097/YCO.0b013e3281568d7a
5. World Health Organization. International Classification of Diseases for Mortality and Morbidity Statistics (ICD-11). Geneva: WHO; 2019.
6. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology. 2012;26(3):422-440. doi:10.1037/a0029037
7. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204-211. doi:10.1192/bjp.bp.107.048827
8. Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5(3):143-154. doi:10.1177/108705470200500302
9. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. doi:10.1016/S0140-6736(14)61684-6
10. Castellanos FX, Tannock R. Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002;3(8):617-628. doi:10.1038/nrn896
11. Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1361-1369. doi:10.1016/j.biopsych.2006.06.011
12. Volkow ND, Wang GJ, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21(2):RC121. doi:10.1523/JNEUROSCI.21-02-j0001.2001
13. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-575. doi:10.1038/s41380-018-0070-2
14. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17(1):61-72. doi:10.1007/s11065-007-9021-2
15. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate. Am J Psychiatry. 2003;160(11):1909-1918. doi:10.1176/appi.ajp.160.11.1909
16. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57(7-8):608-618. doi:10.1016/j.neuropharm.2009.08.008
17. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP104) in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(6):737-747. doi:10.1089/cap.2007.0037
18. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83. doi:10.1542/peds.108.5.e83
19. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784. doi:10.1097/00004583-200207000-00008
20. Scahill L, Chappell PB, Kim HS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074. doi:10.1176/appi.ajp.158.7.1067
21. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. doi:10.1001/archpsyc.1995.03950180030005
22. Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
23. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;(11):CD009885. doi:10.1002/14651858.CD009885.pub2
24. Elliott JM, Johnston A, Husereau D, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. PLoS One. 2020;15(10):e0240584. doi:10.1371/journal.pone.0240584
25. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S63620
26. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-364. doi:10.1007/s00787-009-0054-3
27. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
28. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.4. Cochrane; 2023.
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174. doi:10.2307/2529310
30. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
32. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press; 1985.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
34. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. doi:10.1002/sim.1186
35. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101-129. doi:10.2307/3001666
36. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. doi:10.1136/bmj.39489.470347.AD
37. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406. doi:10.1016/j.jclinepi.2010.07.015
38. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48. doi:10.18637/jss.v036.i03
39. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
40. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784. doi:10.1097/00004583-200207000-00008
41. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-analysis. CNS Drug Rev. 2006;12(2):131-143. doi:10.1111/j.1527-3458.2006.00131.x
42. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001;931:1-16. doi:10.1111/j.1749-6632.2001.tb05770.x
43. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP104) in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(6):737-747. doi:10.1089/cap.2007.0037
44. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83. doi:10.1542/peds.108.5.e83
45. Scahill L, Chappell PB, Kim HS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074. doi:10.1176/appi.ajp.158.7.1067
46. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. doi:10.1001/archpsyc.1995.03950180030005
47. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17(1):61-72. doi:10.1007/s11065-007-9021-2
48. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical practice and policy. Biol Psychiatry. 2006;59(11):990-996. doi:10.1016/j.biopsych.2005.09.014
49. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. doi:10.1002/sim.1186
50. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-364. doi:10.1007/s00787-009-0054-3
51. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S63620
52. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
53. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;(11):CD009885. doi:10.1002/14651858.CD009885.pub2
54. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-364. doi:10.1007/s00787-009-0054-3
55. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S63620
56. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17(1):61-72. doi:10.1007/s11065-007-9021-2
57. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629
58. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. doi:10.1002/sim.1186
59. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S63620
60. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
61. Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
62. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-analysis. CNS Drug Rev. 2006;12(2):131-143. doi:10.1111/j.1527-3458.2006.00131.x
63. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784. doi:10.1097/00004583-200207000-00008
64. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. doi:10.1001/archpsyc.1995.03950180030005
65. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/S2215-0366(18)30269-4
66. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17(1):61-72. doi:10.1007/s11065-007-9021-2
67. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776-784. doi:10.1097/00004583-200207000-00008
68. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52(6):444-455. doi:10.1001/archpsyc.1995.03950180030005
69. Scahill L, Chappell PB, Kim HS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074. doi:10.1176/appi.ajp.158.7.1067
70. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001;931:1-16. doi:10.1111/j.1749-6632.2001.tb05770.x
71. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(5):e1494-e1502. doi:10.1542/peds.2007-1904
72. Wolraich ML, Hagan JF, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528
73. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353-364. doi:10.1007/s00787-009-0054-3
74. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569. doi:10.2147/NDT.S63620
75. Elliott JM, Johnston A, Husereau D, et al. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: a systematic review and network meta-analysis. PLoS One. 2020;15(10):e0240584. doi:10.1371/journal.pone.0240584
76. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-575. doi:10.1038/s41380-018-0070-2
77. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. doi:10.1016/S0140-6736(14)61684-6
78. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-analysis. CNS Drug Rev. 2006;12(2):131-143. doi:10.1111/j.1527-3458.2006.00131.x
